Ken Griffin Dynavax Technologies Corp Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 59,500 shares of DVAX stock, worth $665,210. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,500

Previous 66,800 10.93%

Holding current value

$665,210

Previous $933,000 20.9%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$11.7 - $14.98 $1.83 Million - $2.35 Million	-156,605 Reduced 60.35%	102,907 $1.28 Million
Q4 2023 Feb 14, 2024	SELL	$13.09 - $14.98 $30.7 Million - $35.1 Million	-2,344,938 Reduced 90.04%	259,512 $3.63 Million
Q3 2023 Nov 14, 2023	BUY	$12.64 - $14.99 $1.93 Million - $2.28 Million	152,306 Added 6.21%	2,604,450 $38.5 Million
Q2 2023 Aug 14, 2023	BUY	$9.85 - $13.17 $23.2 Million - $31 Million	2,356,237 Added 2456.79%	2,452,144 $31.7 Million
Q1 2023 May 15, 2023	SELL	$9.44 - $11.88 $6.85 Million - $8.62 Million	-725,436 Reduced 88.32%	95,907 $940,000

Q4 2022 Feb 14, 2023	BUY	$10.27 - $13.29 $4.35 Million - $5.63 Million	423,446 Added 106.42%	821,343 $8.74 Million
Q3 2022 Nov 14, 2022	SELL	$9.93 - $17.44 $466,978 - $820,150	-47,027 Reduced 10.57%	397,897 $4.15 Million
Q2 2022 Aug 15, 2022	BUY	$7.45 - $12.83 $540,788 - $931,316	72,589 Added 19.5%	444,924 $5.6 Million
Q1 2022 May 16, 2022	BUY	$9.75 - $14.44 $1.43 Million - $2.12 Million	146,659 Added 64.99%	372,335 $4.04 Million
Q4 2021 Feb 14, 2022	SELL	$13.17 - $20.94 $1.15 Million - $1.82 Million	-86,941 Reduced 27.81%	225,676 $3.18 Million
Q3 2021 Nov 15, 2021	BUY	$9.16 - $19.83 $1.75 Million - $3.78 Million	190,590 Added 156.19%	312,617 $6.01 Million
Q2 2021 Aug 16, 2021	BUY	$7.25 - $10.99 $322,175 - $488,373	44,438 Added 57.27%	122,027 $1.2 Million
Q1 2021 May 17, 2021	BUY	$4.57 - $11.18 $36,390 - $89,026	7,963 Added 11.44%	77,589 $763,000
Q4 2020 Feb 16, 2021	SELL	$3.73 - $5.6 $7.56 Million - $11.4 Million	-2,027,971 Reduced 96.68%	69,626 $310,000
Q3 2020 Nov 16, 2020	SELL	$4.32 - $11.7 $3.6 Million - $9.74 Million	-832,858 Reduced 28.42%	2,097,597 $9.06 Million
Q2 2020 Aug 14, 2020	BUY	$2.94 - $9.1 $7.28 Million - $22.5 Million	2,475,350 Added 543.91%	2,930,455 $26 Million
Q1 2020 May 15, 2020	BUY	$2.27 - $6.2 $875,234 - $2.39 Million	385,566 Added 554.46%	455,105 $1.61 Million
Q4 2019 Feb 14, 2020	BUY	$3.46 - $6.93 $184,895 - $370,325	53,438 Added 331.89%	69,539 $398,000
Q3 2019 Nov 14, 2019	SELL	$2.69 - $4.85 $1.71 Million - $3.08 Million	-634,219 Reduced 97.52%	16,101 $57,000
Q2 2019 Aug 14, 2019	SELL	$3.65 - $7.89 $1.07 Million - $2.32 Million	-294,430 Reduced 31.16%	650,320 $2.6 Million
Q1 2019 May 15, 2019	BUY	$7.08 - $12.09 $1.64 Million - $2.8 Million	231,948 Added 32.54%	944,750 $0
Q4 2018 Feb 14, 2019	SELL	$8.14 - $13.28 $1.29 Million - $2.11 Million	-158,523 Reduced 18.19%	712,802 $6.52 Million
Q3 2018 Nov 13, 2018	BUY	$11.85 - $16.0 $9.12 Million - $12.3 Million	769,376 Added 754.67%	871,325 $0
Q2 2018 Aug 10, 2018	SELL	$15.15 - $20.75 $5.64 Million - $7.73 Million	-372,553 Reduced 78.51%	101,949 $0
Q1 2018 May 11, 2018	BUY	$14.65 - $19.9 $3.65 Million - $4.96 Million	249,203 Added 110.61%	474,502 $9.42 Million
Q4 2017 Feb 09, 2018	SELL	$17.3 - $24.08 $15.6 Million - $21.8 Million	-903,262 Reduced 80.04%	225,299 $4.21 Million
Q3 2017 Nov 09, 2017	BUY	$15.2 - $21.5 $17.2 Million - $24.3 Million	1,128,561	1,128,561 $24.3 Million

Others Institutions Holding DVAX

# of Institutions

269

Shares Held

132M

Call Options Held

326K

Put Options Held

758K

View Full List

About DYNAVAX TECHNOLOGIES CORP

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.41B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

More about DVAX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account